BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AZD2389 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AZD2389\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07610837-11159@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20270707
DTEND;VALUE=DATE:20270708
SUMMARY:AZD2389: Phase 2 readout est. (NCT07610837)
DESCRIPTION:AZD2389\, phase 2.\nStudy: Study of AZD2389 Safety\, Tolerabili
 ty\, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advan
 ced Fibrosis\nEstimated primary completion: 7 July 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/azd2389#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07610837
URL:https://assetmemo.bio/drug/azd2389#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
